§1.1 Mechanism and Epidemiology
PMID: 21233397 | Design: Retrospective | n: 1,001 | Journal: J Androl
Key findings: Largest PD cohort study. 74% mild-moderate curvature (≤60°). Independent predictors of curvature severity: age (P=.013), deformity side (P=.007), ED (P<.0001), diabetes (P=.001). ED was MORE common in milder deformity groups — proposed explanation: less intercourse → less cumulative trauma → less severe curvature. DM patients: mean curvature 45.2° vs 30.2° without DM. Dorsal curvature associated with more severe deformity (tunica thicker dorsally). Left-sided curvature 3× more frequent than right.
Limitations: Retrospective, single center, lacked obesity/smoking/testosterone data.
PMID: 38893650 | Design: Retrospective | n: 564 | Journal: Diagnostics
Key findings: 88.4% significant anxiety (GAD-7 >9). 38.8% severe anxiety. 57.6% significant depression (PHQ-9 >9). 24.2% were ≤40 years. 35.6% chronic prostatitis. 35.6% plaque calcification. 88.2% had penile shortening (most common deformity). 16.1% multifocal plaque. Active phase documented at 22-26 months in 5 patients — pain absent but curvature still worsening. Only 29% recalled specific penile trauma. ED pre-existed PD in 56.4% of PD+ED cases. Younger patients had more pain; older patients had more ED. IIEF did NOT correlate with curvature severity (p=0.359), plaque volume (p=0.09), or disease duration (p=0.554).
Limitations: 99.1% Caucasian, Italian single-center, specialist-seeking active-phase population only. Community rates likely differ. Referral bias elevates anxiety/depression rates.
§2.1 Guidelines Comparison
PMID: 41795618 | Design: Guideline synthesis | Journal: BJU Int
Key finding: Cross-society comparison of AUA/EAU/CUA/ISSM. Significant divergences on verapamil (AUA conditional, CUA recommends, EAU against), CCH (EAU strongest endorsement at Level 1b), HA (EAU/ICSM against outside trials). North American guidelines more permissive than EAU.
⊕ Correction: Chierigo rendered CUA's verapamil position as Level 2, Grade B. Primary source (Bella 2018) shows Level 3, Grade C. GoG overstated CUA's evidence grading.
PMID: 26066402 | Design: Systematic review, 303 articles | Journal: J Urol
Key findings: Verapamil: "Conditional Recommendation, Grade C" — "the evidence for the use of intralesional verapamil is weak; clinicians should carefully consider whether use of this treatment is appropriate given the substantial uncertainty regarding its efficacy and the availability of other treatments that are clearly more effective." CCH: "Moderate Recommendation, Grade B" — "a modest difference of 7.7°." ESWT: "overall utility of ESWT in the management of PD is low." Traction: "insufficient evidence" (Other Treatments table). IFN: "most appropriate for the patient with stable disease."
PMID: 29792593 | Design: Expert consensus, literature cutoff 6/30/2017 | Journal: CUAJ
Key findings: Only major society that RECOMMENDS intralesional verapamil (Level 3, Grade C) — "widely used in Canada with more than two decades of experience." Recommends traction (Level 4, Grade C). HA: "too early to make any recommendations." ⊕ Internal inconsistency: cites Favilla 2017 (ref 52) for HA evidence but does NOT reconcile the zero verapamil finding with ongoing verapamil recommendation. Plication perception gap (Hudak): 84% no measurable SPL decrease, 78% perceived reduction.
§3A — CCH (Xiaflex)
PMID: 36278151 | Design: Meta-analysis, 11 prospective studies | n: 1,480 | Journal: Front Pharmacol
Key findings: 35% pooled curvature improvement (I²=0.00% — zero heterogeneity). 41% PD bother improvement. 93% TRAEs (mostly mild). Modified protocols may retain same effectiveness. No publication bias for curvature outcome.
Gelbard 2013 — IMPRESS I+II (abstract only for primary, cited in multiple sources)
PMID: 23376148 | Design: Double-blind RCT | n: 832
Key findings: CCH -17° (-34%) vs placebo -9.3° (-18%), P<0.0001. AUA characterizes the net difference as "a modest difference of 7.7°." 46% met composite responder criteria (≥20% curvature improvement + >1-point PDQ bother reduction). 3 corporal ruptures (0.36%). 84.2% of CCH patients had ≥1 adverse event vs 36.3% placebo. A separate Phase IIb study (Gelbard 2012, Levine 2012 — outside the IMPRESS Phase III publication) reported no significant benefit in the non-modeling arm; the citation chain for this claim is via secondary review rather than the primary IMPRESS Phase III paper. Modeling contributes substantially to outcomes. Exclusions: hourglass, ED, ventral curvature, significant calcification — pre-selected favorable population.
PMID: 36127227 | Design: Retrospective | n: 114 | Journal: J Sex Med
Key findings: 44% improved, 39% no change, 17% worsened (improvement threshold has internal inconsistency: abstract says ≥20%, Table 2 footnote says ≥25%). Among responders: mean -22° (-41%). Baseline curvature THE predictor: OR 1.33 per 10° (P=.02). By baseline: ≤30°: 29%, 31-59°: 43%, ≥60°: 60%. Calcification NS (OR 0.92, P=.88 — likely underpowered, ~15% calcified). Cycle-2 decision principle supported. Traction 2-6h/day.
PMID: 40223660 | Design: Retrospective 7-year | n: 292 | Journal: J Sex Med
Key findings: 70.89% compliance. Compliant: 44.44% curvature reduction vs non-compliant 33.33% (P=.034). Dorsal among the best response categories (50.09%); ventrolateral comparable (50.72%) and multiple-curvature highest (~56%); ventral worst (33.57%). 4 suspected penile fractures (1.4%) reported during the study period in patients on standardized 3×/day modeling. Non-compliance: AEs 15.1%, early satisfaction 14.1%, unknown 45.4%.
Limitations: Single-center tertiary referral. 7-year retrospective. Adverse-effect-driven non-compliance limits per-protocol curvature interpretation.
Cao 2022 (RCT Meta-analysis)
PMID: 35252236 | Design: Meta-analysis, 5 RCTs | n: 1,227 | Journal: Front Med
Key findings: CCH significant for curvature (P<0.001) and bother (P<0.001). Pain: NO difference vs placebo (P=0.39). TAE OR 12.86 (P<0.001). No industry funding.
Limitations: Only 5 RCTs available for inclusion (industry funding history of CCH program is documented in the underlying IMPRESS publications, not in this meta-analysis).
PMID: 29733116 | Design: Prospective multicenter | n: 135 | Journal: Andrology
Key findings: Ralph's shortened protocol: 3 injections of 0.9mg at 4-week intervals + daily modeling/stretching/vacuum 2×/day. 94.8% improved (ANY decrease — loose definition). Mean -19.1° (-42.9%). 0% Clavien III complications. 92.6% ecchymosis. Higher dose (0.9mg vs IMPRESS 0.58mg) explains higher bruising rate.
PMID: 30956106 | Design: Retrospective comparative | n: 113
Key findings: CCH + RestoreX: -33.8° vs CCH alone -20.3° vs CCH + conventional traction -19.2°. RestoreX patients 6.9× more likely to achieve ≥20° improvement. Abstract-only — cited via ESSM position statement (García-Gómez 2021).
Cocci 2020 (abstract only — paywall)
PMID: 32342279 | Design: Prospective single-arm | n: 74 | Journal: Clin Drug Invest
Key findings: Single CCH injection in acute phase: -19.3° (P<0.0001). Baseline curvature and time since onset predicted improvement. Off-label for acute phase. Uncontrolled.
PMID: 33684795 | Design: Claims database, PS-matched | n: 620/cohort | Journal: Sex Med
Key findings: CCH fewer post-procedural complications (18.4% vs surgery 25.3%, P=.003). Less ED (44.8% vs 65.0%). Less opioid use (38.9% vs 93.3%). Corporal rupture: CCH 1.8% vs surgery 0.8% (NS).
Limitations: Claims-based — no clinical curvature measurements. Endo Pharmaceuticals-funded.
PMID: 35013566 | Design: Claims database | n: 1,227+620 | Journal: Int J Impot Res
Key findings: CCH first → 4.6% subsequent surgery (12 months) vs surgery first → 10.3% (P<0.0001). Difference narrowed at 24 months (8.7% vs 10.7%, NS). Prior CCH does NOT increase surgical complications.
Limitations: Claims-based. Endo Pharmaceuticals-funded. Lead-time bias acknowledged.
Calcification Evidence — Genuinely Unsettled
PMID: 29908867 | Design: Retrospective | n: 115
Key findings: Noncalcified patients OR 2.50 for CCH improvement. 67% noncalcified vs 41% calcified improved.
PMID: 36272924 | Design: Prospective (per PubMed abstract; primary article not on disk) | n: 47
Key findings: Calcified patients CAN improve with CCH (-17.5°). Contradicts Wymer — needs reconciliation.
Calcification evidence status (updated with Cahill 2025): Three data points — one positive (Wymer, n=115), one contradictory (Masterson, n=47), one NS in the largest series (Cahill, n=826, P=.37). Weight of evidence now favors: calcification is NOT a reliable predictor of CCH failure. Partial calcification is not a contraindication. ICSM 2024: "calcification does not signify chronic disease — may represent a different genetic subtype." See consolidated Cahill 2025 entry below.
PMID: 35461065 | Design: Claims database | n: 89,205 | Journal: Sex Med
Key findings: CCH $6,940-8,895/cycle, median 2 cycles = ~$15-18K total. OOP <$300/cycle. Surgery $1,856-3,631. Verapamil ~$60/year.
Cited via: Ziegelmann 2020 (secondary source — primary paper: Tsambarlis et al. 2019, Int J Impot Res, ref 87 in Ziegelmann)
Design: Post-approval | n: 45
Key finding: Real-world mean curvature reduction 5.4° — vs IMPRESS 17°. Real-world efficacy gap.
Cahill 2025 — LARGEST PROSPECTIVE CCH PREDICTOR STUDY
PMID: 40814201 | Design: Prospective sequential database | n: 826 | Journal: J Sex Med 2025
Key findings:
- Median curvature improvement: 27.5° (Most Recent) / 32.5° (Completed 8 or Satisfied). ⚠️ Trost-protocol specific — uses aggressive in-office modeling, 0.9mg dose, wrapping, and RestoreX in 98% of patients. NOT standard IMPRESS protocol. Not generalizable to community CCH practice.
- RestoreX: Associated with 19.5° greater improvement on multivariate (P=.02). The strongest predictor across all models. ⚠️ Confound: By 2019+, 98% used RestoreX → insufficient power in non-use arm → cannot cleanly separate RestoreX benefit from concurrent protocol changes.
- Hourglass/indentation: Moderate/severe → 3-10° MORE improvement than none/mild (P<.0001 univariate; multivariate P=.02). Counterintuitive: More severe indentation predicts BETTER CCH response. Contradicts prior assumption that hourglass precludes CCH.
- Calcification: NS (P=.37) — not a significant predictor. See calcification evidence status above (Wymer/Masterson/Cahill synthesis).
- Active phase: NS (P=.48) — CCH may safely and effectively be used in active phase.
- Disease duration: NS (P=.37) — duration does not predict outcomes.
- Lateral curvature: -11.2° worse outcomes (multivariate P<.001). Dorsal/dorsolateral: best response.
- Motivation/bother: Higher PDQ bother and psych/physical scores correlated with better outcomes. Decreased self-reported motivation: 7° worse.
- Controlled fracture: Popping sensation +4.4° (P<.01), rapid detumescence +4.6° (P<.01) — from aggressive in-office modeling.
- IIEF: Zero change post-CCH across all domains (consistent with Osmonov: IIEF not validated for PD).
- 44% completed 4 series or stopped satisfied — consistent with Flores 44%.
Limitations: Single-center (Trost's clinic, Utah). Protocol evolved substantially over 10 years. RestoreX confound. ⚠️ Triple COI: Trost is inventor of RestoreX, part-owner of PathRight Medical, and received investigator-initiated grants from Endo Pharmaceuticals (CCH manufacturer). Also Editor-in-Chief of J Sex Med (the publishing journal). Declared; editorial process delegated.
§3B — Hyaluronic Acid
PMID: 28718527 | Design: Double-blind RCT | n: 140 (69V/63HA) | Journal: Andrology
Key findings: Verapamil: 0.00° ± 0.00 curvature change. HA: -4.60° (P<0.001). Both reduced plaque (-1.36mm vs -1.80mm, NS). Both improved IIEF (NS between groups). HA PGI-I: 3.13 vs V 3.53 (P<0.05). No injection-site ecchymosis, hematomas, or other significant adverse events reported. Acute phase, 11 Italian centers, weekly × 12 weeks.
PMID: 39355797 | Design: Double-blind RCT | n: 42 | Journal: Arab J Urol
Key findings: HA -9.4° vs V -5.4° (P=0.038). HA better for plaque size (P<0.001 vs NS for V). Acute phase. Small sample.
PMID: 38305689 | Design: Retrospective | n: 62 | Journal: Asian J Androl
Key findings: Only HA study in stable phase. 3 injections at 2-week intervals + vacuum + stretching + modeling. 87.1% responded. Mean -12.4° (23%). Calcification NOT predictive (P=0.847). No long-lasting local adverse effects reported. Cannot separate HA effect from mechanical adjunct.
Guideline status (2026): EAU recommends AGAINST outside clinical trials (Level 3c, Strong). ICSM 2024: "does not support." Approved only in Italy.
§3D — Verapamil
Verapamil arm: 0.00° ± 0.00. Zero curvature change in the only double-blind RCT.
Verapamil -2.1° vs placebo -2.2°. NS. n=80.
PMID: 21950543 | Design: Retrospective, uncontrolled | n: 151
Key findings: Best combo (Group 2: verapamil injection + iontophoresis + vit E + diclofenac + propolis): -14°. Group 3 (verapamil injection + vit E + topical diclofenac, no iontophoresis or propolis): -2.7°. Group 4 (verapamil iontophoresis + vit E + topical diclofenac, no injection): -4.5°. None of the arms tested verapamil monotherapy. Active ingredient may be propolis (NF-κB inhibitor), not verapamil.
PMID: 12454681 | Design: Uncontrolled | n: 156
Key findings: 60% "objectively improved." No placebo. 30.4 months follow-up. The foundational verapamil paper. Stub — limited content.
Pattern: Uncontrolled studies positive. Every controlled trial negative.
§4 — Decision Factors + Surgical Evidence
Osmonov 2022 (ESSM Position Statement)
PMID: 34823053 | Design: Systematic review, 131 studies | Journal: Sex Med
Key findings: 18 position statements. Plication: straightening 48-100%, satisfaction 58-96%. Grafting: recurrence 50-87% long-term. TachoSil: 83-95% straightening, 91.5% satisfaction, shortest operative time. Glans hypoesthesia: plication up to 53%, grafting up to 39% — mostly transient. Statement #14: post-CCH surgery feasible without increased complications (harder within 3 months). >70% of patients report penile shortening BEFORE surgery. IIEF not validated for PD — all surgical ED outcome data uses a non-validated instrument.
Limitations: Literature 2009-2019 only. Misses RestoreX RCT and all post-2019 data.
PMID: 38388784 | n: 91
Key finding: Plication does NOT cause additional length loss (P=0.466). "The perceived length loss has already occurred prior to surgery." Perception gap (Hudak): 84% no measurable loss, 78% perceived loss.
PMID: 29644164 | Design: Retrospective | n: 17 with follow-up (36 total) | Journal: Transl Androl Urol
Key findings: Extra-tunical grafting (ETG) for hourglass/indentation. All 17 reported satisfactory resolution — but 13/17 had concurrent plication. 94.1% satisfied, 11.8% mild hypoesthesia, zero ED worsening. ETG does NOT violate tunica albuginea or dissect NVB. Also used for post-CCH corporeal herniation. Graft initially more prominent in flaccid state, normalizes by 6 months.
Limitations: n=17, retrospective, single surgeon, no validated questionnaire, plication confound in 76% of cohort. Promising preliminary evidence, not established efficacy.
